Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02107963CT.gov A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Gd2-Car Engineered T Cells (this asset) | National Cancer Institute (NCI) | P1 | CC · 44 |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| (+)-Vincristine | Milton S. Hershey Medical Center | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| Etoposide | Eisai Limited | P2 | B |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | B |
| Irinotecan | Milton S. Hershey Medical Center | P2 | B |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | B |
+42 more in the Osteosarcoma cohort
Other indications for Anti-Gd2-Car Engineered T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroblastoma | — | P1/2 | CCC · 53 |
| Sarcoma | — | P1 | CC · 42 |
| Melanoma | — | P1 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Gd2-Car Engineered T Cells in Osteosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-gd2-car-engineered-t-cells-osteosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →